Full-Time
Affiliates Executive
Performance Marketing
Posted on 9/1/2025
Pattern Bioscience
51-200 employees
AI-driven rapid bacterial ID and AST
No salary listed
Sydney NSW, Australia
Hybrid
Hybrid working options available.
 Growth & Marketing (1) |
|---|
- 2-3 years of Performance Marketing implementation in an agency
- 1-2 years of ecommerce implementation across Affiliates channels including account management
- A background in developing relationships with both internal and client side stakeholders at various levels
- Advanced knowledge of key platforms: Rakuten, Commission Factory, Impact & GA4
- Excellent attention to detail, communication skills
- Experience with Google Docs/Drive, Excel & Google Analytics
- Executing the Affiliates channel across a range of ecommerce clients, including uploading offers to platforms, negotiating and maintaining relationships with partners, coordinating campaign activity, analysing performance, generating reports, and delivering end-of-month summaries
- Help problem solve/troubleshoot implementation issues and improve client performance to exceed client KPIs
- Assist the Senior Affiliates Manager to develop Pattern’s Affiliates product offering in line with best in class, and setting the standard for best practice implementation across new and emerging channel
- Be involved in the account management of all Affiliate clients
- Actively stay up to date with new affiliate trends and platform updates
- Assist in preparing new business proposals to showcase our strategic thinking, best practice approach and product offering
- Working closely with the Senior Affiliates Manager on project work, such as audits and strategies
Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.
Company Size
51-200
Company Stage
Series D
Total Funding
$91.6M
Headquarters
Austin, Texas
Founded
2016
Simplify's Take
What believers are saying
- $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
- $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
- Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.
What critics are saying
- Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
- BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
- Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.
What makes Pattern Bioscience unique
- Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
- Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
- Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Pattern Bioscience who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 1%Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.
To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.
Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform
Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.
Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.